Evotec is to acquire Kinaxo Biotechnologies, a German drug discovery services company, in a cash and stock deal worth around €16 million.
Evotec will pay €3 million in cash and issue about 2.6 million shares of its stock to Kinaxo.
Evotec is to acquire Kinaxo Biotechnologies, a German drug discovery services company, in a cash and stock deal worth around €16 million.
Evotec is to acquire Kinaxo Biotechnologies, a German drug discovery services company, in a cash and stock deal worth around €16 million.
Evotec will pay €3 million in cash and issue about 2.6 million shares of its stock to Kinaxo.
The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.
A deal last year with Sanofi relieved Novavax of commercial costs for the COVID-19 vaccine Nuvaxovid, allowing the company to focus on R&D and finding partners for its other vaccines.
The Austrian firm is delisting from the NASDAQ and closing down.
Sino Biopharm will pay almost $1bn to acquire what target LaNova’s CEO described as an “exploding” pipeline, which includes six clinical-stage candidates in the oncology area.
Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.
Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.
As AI-driven firms including Insilico, big pharmas J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?